Lupin launches Loteprednol Etabonate ophthalmic suspension 0.5% in US
Loteprednol Etabonate Ophthalmic Suspension, 0.5% is indicated for the treatment of steroidresponsive inflammatory conditions of the palpebral and bulbar conjunctiva
Loteprednol Etabonate Ophthalmic Suspension, 0.5% is indicated for the treatment of steroidresponsive inflammatory conditions of the palpebral and bulbar conjunctiva
Godavari Biorefineries receives patent from CNIPA
The transaction, approved by both companies' boards of directors, is expected to close by the end of the first quarter of 2026
The program will offer a structured and immersive learning experience for over 20,000 healthcare professionals across more than 10 cities
Capricor’s BLA for Deramiocel received Priority Review in March 2025
LEQSELVI now available for prescription in U.S. nationwide, offering a new option for eligible patients
The company’s largest center for medical device applications, serving the entire Asian market
Apotex will also pay US$ 2.5 million upon receipt of final USFDA approval of the ANDA that is the subject of the Collaboration Agreement for Paclitaxel Protein-Bound Particles for Injectable Suspension
Subscribe To Our Newsletter & Stay Updated